Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease
Cells · 01.05.2023 · 12 (9) · 1292
DOI: 10.3390/cells12091292 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 01.05.2023. Verfasst von Hyejin Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Sookmyung Women's University, Seoul 04310, Republic of Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Non-alcoholic fatty liver disease (NAFLD) refers to a range of conditions in which excess lipids accumulate in the liver, possibly leading to serious hepatic manifestations such as steatohepatitis, fibrosis/cirrhosis and cancer. Despite its increasing prevalence and significant impact on liver disease-associated mortality worldwide, no medication has been approved for the treatment of NAFLD yet. Liver X receptors α/β (LXRα and LXRβ) are lipid-activated nuclear receptors that serve as master regulators of lipid homeostasis and play pivotal roles in controlling various metabolic processes, including lipid metabolism, inflammation and immune response. Of note, NAFLD progression is characterized by increased accumulation of triglycerides and cholesterol, hepatic de novo lipogenesis, mitochondrial dysfunction and augmented inflammation, all of which are highly attributed to dysregulated LXR signaling. Thus, targeting LXRs may provide promising strategies for the treatment of NAFLD. However, emerging evidence has revealed that modulating the activity of LXRs has various metabolic consequences, as the main functions of LXRs can distinctively vary in a cell type-dependent manner. Therefore, understanding how LXRs in the liver integrate various signaling pathways and regulate metabolic homeostasis from a cellular perspective using recent advances in research may provide new insights into therapeutic strategies for NAFLD and associated metabolic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Sookmyung Women's University, Seoul 04310, Republic of Korea.
- Drug Information Research Institute, Sookmyung Women's University, Seoul 04310, Republic of Korea.
- Muscle Physiome Research Center, Sookmyung Women's University, Seoul 04310, Republic of Korea.
ORCID-Profile: Tae Hyun Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, H., Park, C., & Kim, T. H. (2023). Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells, 12(9), 1292. https://doi.org/10.3390/cells12091292
Vancouver
Kim H, Park C, Kim TH. Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells. 2023;12(9):1292. doi:10.3390/cells12091292
BibTeX
@article{Kim2023,
author = {Kim, Hyejin and Park, Chaewon and Kim, Tae Hyun},
title = {Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease},
journal = {Cells},
year = {2023},
volume = {12},
number = {9},
pages = {1292},
doi = {10.3390/cells12091292}
}
EUVIMED